Back to Search
Start Over
Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy
- Source :
- Journal of Cancer Research and Clinical Oncology; 20001117, Vol. 126 Issue: 12 p722-729, 8p
- Publication Year :
- 2000
-
Abstract
- Abstract: Purpose: Adjuvant therapy has become an integral component of the management of primary high-risk breast cancer patients. However, a considerable fraction of women receive no benefit from this treatment. This study investigates whether a number of biopathological factors can influence the outcome of patients submitted to adjuvant chemotherapy involving the use of high-dose epirubicin and cyclophosphamide. Methods: One hundred and fifty-seven primary breast cancer patients, considered at high risk according to the St. Gallen Meeting Consensus Conference, were evaluated immunohistochemically for estrogen, progesterone receptors, p53, bcl-2, HER-2/neu, and Ki-67, of which the results were correlated with patient outcome. Results: Results obtained demonstrated that p53 is a significant predictor of disease-free survival (DFS P < 0.0001) and overall survival (OS P=0.0002) both in ductal and lobular carcinomas, whereas bcl-2 expression seems to be of prognostic value only in lobular carcinomas (DFS P=0.01; OS P=0.02). Conclusions: This data indicates that in high-risk breast cancer patients the immunohistochemical evaluation of p53 and bcl-2 may be of clinical value in distinguishing different responses to adjuvant anthracycline-based chemotherapy.
Details
- Language :
- English
- ISSN :
- 01715216 and 14321335
- Volume :
- 126
- Issue :
- 12
- Database :
- Supplemental Index
- Journal :
- Journal of Cancer Research and Clinical Oncology
- Publication Type :
- Periodical
- Accession number :
- ejs12151753
- Full Text :
- https://doi.org/10.1007/PL00008478